BCM
CAMP icon

Bridgeway Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Bridgeway Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Hold
25,000
– – ﹤0.01% 1117
2025
Q4 		$153K Hold
25,000
– – ﹤0.01% 1063
2025
Q3 		$75K Hold
25,000
– – ﹤0.01% 1136
2025
Q2 		$36.3K Buy
+25,000
New +$49.8K ﹤0.01% 1147

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bridgeway Capital Management's CAMP Position: Q1 2026 in Review

Bridgeway Capital Management held its CAMP4 Therapeutics (CAMP) position steady in Q1 2026 at 25,000 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1117.

Bridgeway Capital Management first reported a position in CAMP in Q2 2025 and has held it in 4 quarters since. The position peaked at $153K in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Bridgeway Capital Management held 25,000 shares of CAMP4 Therapeutics worth $110K as of Q1 2026.
  • Bridgeway Capital Management left its CAMP4 Therapeutics share count unchanged in Q1 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1117 holding.
  • Bridgeway Capital Management first reported a position in CAMP4 Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's CAMP4 Therapeutics position peaked at $153K in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.